JO
RPRX icon

John Overdeck’s Royalty Pharma RPRX Stock Holding History

John Overdeck’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164M Buy
2,920,163
+668,638
+30% +$34.8M 0.12% 189
2026
Q1 		$108M Buy
2,251,525
+1,570,277
+231% +$68.8M 0.09% 262
2025
Q4 		$26.3M Sell
681,248
-503,063
-42% -$19.2M 0.04% 592
2025
Q3 		$41.8M Buy
1,184,311
+1,130,209
+2,089% +$40.9M 0.06% 373
2025
Q2 		$1.95M Sell
54,102
-1,558,907
-97% -$51.6M ﹤0.01% 1853
2025
Q1 		$50.2M Sell
1,613,009
-807,394
-33% -$25.6M 0.11% 235
2024
Q4 		$61.7M Sell
2,420,403
-8,933
-0.4% -$237K 0.13% 181
2024
Q3 		$68.7M Buy
2,429,336
+371,796
+18% +$10.3M 0.15% 162
2024
Q2 		$54.3M Buy
2,057,540
+753,881
+58% +$20.9M 0.12% 194
2024
Q1 		$39.6M Sell
1,303,659
-807,609
-38% -$23.8M 0.09% 271
2023
Q4 		$59.3M Sell
2,111,268
-95,447
-4% -$2.62M 0.14% 189
2023
Q3 		$59.9M Buy
2,206,715
+1,075,019
+95% +$31.9M 0.16% 173
2023
Q2 		$34.8M Buy
1,131,696
+957,412
+549% +$32.4M 0.09% 282
2023
Q1 		$6.28M Sell
174,284
-265,825
-60% -$9.86M 0.02% 801
2022
Q4 		$17.4M Sell
440,109
-351,231
-44% -$14.7M 0.05% 391
2022
Q3 		$31.8M Buy
791,340
+320,393
+68% +$13.7M 0.11% 237
2022
Q2 		$19.8M Buy
470,947
+283,920
+152% +$11.6M 0.07% 329
2022
Q1 		$7.29M Buy
187,027
+33,552
+22% +$1.32M 0.02% 741
2021
Q4 		$6.12M Buy
+153,475
New +$5.96M 0.01% 1078

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

John Overdeck's RPRX Position: Q2 2026 in Review

John Overdeck increased its Royalty Pharma (RPRX) stake by 30% in Q2 2026, buying an estimated $34.8M and bringing the position to 2,920,163 shares worth $164M. The position accounts for 0.12% of the portfolio, ranked #189.

John Overdeck first reported a position in RPRX in Q4 2021 and has held it in 19 quarters since. 640 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • John Overdeck held 2,920,163 shares of Royalty Pharma worth $164M as of Q2 2026.
  • John Overdeck bought 668,638 Royalty Pharma shares in Q2 2026, an estimated $34.8M.
  • Royalty Pharma made up 0.12% of John Overdeck's portfolio in Q2 2026, its #189 holding.
  • John Overdeck first reported a position in Royalty Pharma in Q4 2021 and has held it in 19 quarters since.
  • 640 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.